^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alloCART-19 cell therapy

    i
    Other names: alloCART-19 cell therapy
    Associations

    News

    Trials
    Company:
    Fudan University
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Children's Hospital of Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Oct 2023 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD4 (CD4 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • alloCART-19 cell therapy
    2years
    Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=6, Recruiting, Children's Hospital of Fudan University | Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Oct 2021 --> Oct 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • alloCART-19 cell therapy
    4years
    Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=6, Recruiting, Children's Hospital of Fudan University | Trial primary completion date: Oct 2020 --> Oct 2021
    Clinical • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    fludarabine IV • alloCART-19 cell therapy • cyclophosphamide intravenous